カテゴリ： GlobalData, デンマーク, 企業調査

Bavarian Nordic AS (BAVA)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Bavarian Nordic AS (BAVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C5157
◆発行会社（調査会社）：GlobalData
◆発行日：2018年9月
◆ページ数：65
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：デンマーク
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Bavarian Nordic A/S (Bavarian Nordic) is a biotechnology company that develops, manufactures and commercializes cancer immunotherapies and vaccines for infectious diseases. The company develops its products using poxvirus-based technology platforms including vaccinia-fowlpox (VF)-TRICOM and modified vaccinia ankara – bavarian nordic (MVA-BN). Its pipeline products are intended for the treatment of smallpox, prostate cancer, bladder cancer, solid tumors, chronic HPV infection, marburg and ebola infections, and others. Bavarian Nordic has collaboration with US government and various institutes, to develop its product candidates for the treatment of cancer and infectious diseases. It has a presence in the US, Denmark and Germany. Bavarian Nordic is headquartered in Kvistgaard, Denmark.

Bavarian Nordic AS (BAVA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Bavarian Nordic A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bavarian Nordic A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bavarian Nordic A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bavarian Nordic A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Bavarian Nordic A/S, Medical Devices Deals, 2012 to YTD 2018 10
Bavarian Nordic A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Bavarian Nordic A/S, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
PCI Biotech Enters into Research Agreement with Bavarian Nordic 13
Bavarian Nordic Enters into Agreement with US Department of Defense 14
Bavarian Nordic Enters into Partnership with Astrazeneca 15
SGS Partners with Bavarian Nordic 16
Bavarian Nordic Enters into Agreement with Roche 17
Bavarian Nordic Enters into Agreement with Evaxion Biotech and Technical University of Denmark 18
Licensing Agreements 19
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 19
Bavarian Nordic Enters into Licensing Agreement with Valneva 20
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 21
Bristol-Myers Squibb Enters into Option for Licensing Agreement with Bavarian Nordic 22
Bavarian Nordic Enters into Licensing Agreement with Crucell Holland 23
Bavarian Nordic Enters into Licensing Agreement with National Institutes of Health 24
Equity Offering 25
Bavarian Nordic Raises USD32.5 Million in Private Placement of Shares 25
Bavarian Nordic Raises USD101.8 Million in Private Placement of Shares 27
Bavarian Nordic Withdraws Public Offering of ADSs for up to USD86.3 Million 29
Bavarian Nordic Raises USD0.66 Million in Private Placement of Shares upon Exercise of Warrants 31
Bavarian Nordic Raises USD1.7 Million in Private Placement of Shares upon Exercise of Warrants 32
Bavarian Nordic Raises USD1 Million upon Exercise of Warrants 33
Bavarian Nordic Raises USD1 Million upon Exercise of Warrants 34
Bavarian Nordic Raises USD43 Million in Private Placement of Shares 35
Bavarian Nordic Raises USD3.8 Million in Private Placement of Shares upon Exercise of Warrants 36
Bavarian Nordic A/S – Key Competitors 37
Bavarian Nordic A/S – Key Employees 38
Bavarian Nordic A/S – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Aug 16, 2018: Bavarian Nordic announces first half 2018 results 40
May 24, 2018: Bavarian Nordic Announces Interim Results for the First Three Months of 2018 42
Mar 12, 2018: Bavarian Nordic Announces Annual Report 2017 44
Nov 08, 2017: Bavarian Nordic Announces Interim Results for the First Nine Months of 2017 46
Aug 25, 2017: Bavarian Nordic Announces First Half 2017 Results 47
May 04, 2017: Bavarian Nordic Announces Interim Results for the First Three Months of 2017 48
Mar 15, 2017: Bavarian Nordic Announces Annual Report 2016 49
Corporate Communications 50
May 31, 2018: Bavarian Nordic Appoints Henrik Juuel As Chief Financial Officer 50
Jan 31, 2018: Bavarian Nordic Announces Resignation Of Ole Larsen As Chief Financial Officer 51
May 10, 2017: Bavarian Nordic Announces Appointment of Dr. Tommi Kainu as Chief Business Officer 52
Jan 17, 2017: Henrik Birk Appointed Chief Operating Officer of Bavarian Nordic 53
Product News 54
09/27/2017: Bavarian Nordic Secures Contract Award for Supply of Freeze-dried IMVAMUNE Smallpox Vaccine to the U.S. Government 54
06/16/2017: Bavarian Nordic Announces Notification of Request for Proposal for Freeze-Dried IMVAMUNE 55
03/10/2017: Bavarian Nordic Announces Collaboration to Evaluate CV301 and Tecentriq in Bladder Cancer 56
Clinical Trials 57
Jun 19, 2018: Exploring a New Treatment for Metastatic Colorectal Cancer 57
Mar 08, 2018: Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer 58
Feb 06, 2018: Bavarian Nordic Announces Positive Results of Pivotal Phase 3 Study of IMVAMUNE Smallpox Vaccine 59
Nov 21, 2017: Bavarian Nordic Announces Exercise of Clinical Option by the US Government under Contract for Freeze-dried IMVAMUNE Smallpox Vaccine 60
Mar 21, 2017: Direct Tumor Vaccination Shown to Induce Anti-tumor Immunity and Increase Survival in a Murine Model of Pancreatic Cancer 61
Jan 04, 2017: Bristol-Myers, Bavarian Nordic test Opdivo-plus-vaccine combo in lung cancer 62
Other Significant Developments 63
Aug 09, 2018: Bavarian Nordic granted EUR 30 million loan from The European Investment Bank 63
Mar 12, 2018: Bavarian Nordic Awards Restricted Stock Units to Executive Management 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65

List of Tables
Bavarian Nordic A/S, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Bavarian Nordic A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bavarian Nordic A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bavarian Nordic A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bavarian Nordic A/S, Deals By Therapy Area, 2012 to YTD 2018 9
Bavarian Nordic A/S, Medical Devices Deals, 2012 to YTD 2018 10
Bavarian Nordic A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
PCI Biotech Enters into Research Agreement with Bavarian Nordic 13
Bavarian Nordic Enters into Agreement with US Department of Defense 14
Bavarian Nordic Enters into Partnership with Astrazeneca 15
SGS Partners with Bavarian Nordic 16
Bavarian Nordic Enters into Agreement with Roche 17
Bavarian Nordic Enters into Agreement with Evaxion Biotech and Technical University of Denmark 18
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 19
Bavarian Nordic Enters into Licensing Agreement with Valneva 20
Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 21
Bristol-Myers Squibb Enters into Option for Licensing Agreement with Bavarian Nordic 22
Bavarian Nordic Enters into Licensing Agreement with Crucell Holland 23
Bavarian Nordic Enters into Licensing Agreement with National Institutes of Health 24
Bavarian Nordic Raises USD32.5 Million in Private Placement of Shares 25
Bavarian Nordic Raises USD101.8 Million in Private Placement of Shares 27
Bavarian Nordic Withdraws Public Offering of ADSs for up to USD86.3 Million 29
Bavarian Nordic Raises USD0.66 Million in Private Placement of Shares upon Exercise of Warrants 31
Bavarian Nordic Raises USD1.7 Million in Private Placement of Shares upon Exercise of Warrants 32
Bavarian Nordic Raises USD1 Million upon Exercise of Warrants 33
Bavarian Nordic Raises USD1 Million upon Exercise of Warrants 34
Bavarian Nordic Raises USD43 Million in Private Placement of Shares 35
Bavarian Nordic Raises USD3.8 Million in Private Placement of Shares upon Exercise of Warrants 36
Bavarian Nordic A/S, Key Competitors 37
Bavarian Nordic A/S, Key Employees 38
Bavarian Nordic A/S, Other Locations 39
Bavarian Nordic A/S, Subsidiaries 39

List of Figures
Bavarian Nordic A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bavarian Nordic A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bavarian Nordic A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bavarian Nordic A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bavarian Nordic A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bavarian Nordic A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Bavarian Nordic A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bavarian Nordic A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Bavarian Nordic A/S, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Bavarian Nordic AS (BAVA)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Capital Lease Aviation Limited
    Capital Lease Aviation Limited - Strategy, SWOT and Corporate Finance Report Summary Capital Lease Aviation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Daimler AG (DAI)-エネルギー分野：企業M&A・提携分析
    Summary Daimler AG (Daimler) is an automobile company that undertakes the manufacture, distribution and sales of premium passenger cars, commercial vehicles and related spare part and accessories. The company also provides services such as financing, leasing, fleet management, insurance, financial i …
  • New World Development Company Limited：企業の戦略・SWOT・財務分析
    New World Development Company Limited - Strategy, SWOT and Corporate Finance Report Summary New World Development Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Pearl Global Industries Limited：企業の戦略・SWOT・財務情報
    Pearl Global Industries Limited - Strategy, SWOT and Corporate Finance Report Summary Pearl Global Industries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Progenitor Cell Therapy LLC-製薬・医療分野：企業M&A・提携分析
    Summary Progenitor Cell Therapy LLC (PCT), a subsidiary of Caladrius Biosciences Inc is an external development and manufacturing company that offers cell therapy products. The company offers services that include cell and tissue processing; storage, distribution and delivery; consulting and regulat …
  • DHI Group Inc：企業のM&A・事業提携・投資動向
    DHI Group Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's DHI Group Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Cosan S.A. Industria e Comercio (CSAN3)-エネルギー分野：企業M&A・提携分析
    Summary Cosan S.A. Industria e Comercio (Cosan), a subsidiary of Cosan Limited, is an integrated bioenergy company. It invests in diversified industries, including agribusiness, fuel and natural gas distribution, and lubricants. The company distributes lubricants, fuel oil, and piped natural gas; an …
  • Falck Renewables S.p.A. (FKR)：企業の財務・戦略的SWOT分析
    Falck Renewables S.p.A. (FKR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Sohar Aluminium LLC：企業の戦略・SWOT・財務情報
    Sohar Aluminium LLC - Strategy, SWOT and Corporate Finance Report Summary Sohar Aluminium LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Estchem Co Ltd：企業の戦略的SWOT分析
    Estchem Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Quidel Corp (QDEL)：企業の財務・戦略的SWOT分析
    Quidel Corp (QDEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Mizuho Trust & Banking Co Ltd：企業の戦略・SWOT・財務分析
    Mizuho Trust & Banking Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Mizuho Trust & Banking Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • R Pharm-製薬・医療分野：企業M&A・提携分析
    Summary R Pharm is a pharmaceutical company that offers drug development and manufacturing. The company offers finished dosage forms, active pharmaceutical ingredients (api) and biotechnological substances. It provides products in therapeutic areas of oncology, hematology, immune diseases, antibioti …
  • CTBC Financial Holding Co Ltd (2891)：企業の財務・戦略的SWOT分析
    CTBC Financial Holding Co Ltd (2891) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Grupo Biotoscana SL (GBIO33)：製薬・医療：M&Aディール及び事業提携情報
    Summary Grupo Biotoscana SL (Biotoscana) is a biopharmaceutical company that develops, manufactures and markets advanced medicines for unmet medical needs. The company offers products such as vidaza, ladevina, zyvalix, mielozitidina, votrynib, bozob, timab, enzastar, capebina, leprid, olvestran, toc …
  • Uniper SE (UN01)：企業の財務・戦略的SWOT分析
    Uniper SE (UN01) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • SGL Carbon SE：企業の戦略・SWOT・財務分析
    SGL Carbon SE - Strategy, SWOT and Corporate Finance Report Summary SGL Carbon SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • SunTrust Banks Inc：企業のM&A・事業提携・投資動向
    SunTrust Banks Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's SunTrust Banks Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Municipal Energy Agency of Nebraska：企業の戦略的SWOT分析
    Municipal Energy Agency of Nebraska - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • OBI Pharma Inc (4174)：企業の財務・戦略的SWOT分析
    Summary OBI Pharma Inc (OBI Pharma) is a biopharmaceutical company that develops therapies for the treatment of cancer and infectious diseases. The company’s products include adagloxad simolenin, an active immunotherapy which is intended for the treatment of metastatic breast cancer; and OBI-833, a …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆